Zkusit zdarma
Biogen Inc.

Biogen Inc.

BIIB
Cena:
$ 193.76
+4.29 (2.26%)
Valuace
35
Růst
0
Zdraví
85
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

13:15 22-05-2026

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt d...

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

9:00 22-05-2026

Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for dira...

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

7:50 22-05-2026

U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnol...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

18:40 21-05-2026

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

18:17 21-05-2026

Biogen and Denali Therapeutics said on Thursday ​they will discontinue development of ‌their Par...

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

18:00 21-05-2026

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasd...

Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)

Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB)

9:00 20-05-2026

Biogen stock fell approximately 6.4% in a single session after Phase 2 "CELIA" trial data for dirane...

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud

16:00 19-05-2026

NEW YORK--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) shareholders lost approximately 6.4% of their ...

BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations

BIIB ALERT: Levi & Korsinsky Investigates Biogen Inc. for Possible Securities Fraud Violations

9:50 18-05-2026

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it ha...

BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations

BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations

9:00 18-05-2026

Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed...

Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB)

19:02 15-05-2026

Biogen shares dropped 6.4% after Phase 2 CELIA trial data revealed information absent from the Compa...

Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details

Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details

15:34 15-05-2026

New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it ha...

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal

12:31 15-05-2026

Biogen advances Alzheimer's drug diranersen to late-stage trials after a phase II study misses its m...

Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity

Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity

11:10 15-05-2026

Biogen Inc. is upgraded from Sell to Hold, reflecting recent strategic moves and a modest rebound de...

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

19:10 14-05-2026

Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late...

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

12:10 14-05-2026

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite d...

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

9:07 14-05-2026

Biogen's diranersen showed ‘robust reductions' in key biomarkers during a Phase 2 trial, the biote...

Biogen Completes Acquisition of Apellis Pharmaceuticals

Biogen Completes Acquisition of Apellis Pharmaceuticals

8:35 14-05-2026

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the su...

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

7:05 14-05-2026

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that i...

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

7:03 14-05-2026

Biogen ​said ‌on ​Thursday ​its Alzheimer's ⁠drug ​did ​not meet ​the ​main goal ...

close

BIOGEN ANNOUNCES BOARD CHAIR TRANSITION

11-02-2026
CAROLINE DORSA TO RETIRE FROM THE BIOGEN BOARD OF DIRECTORS; DR. MARIA C. FREIRE, DIRECTOR SINCE 202...
Více zde

NATURE MEDICINE PUBLISHES RESULTS FROM THE PIVOTAL DEVOTE STUDY OF HIGH-DOSE REGIMEN OF NUSINERSEN IN SPINAL MUSCULAR ATROPHY

04-02-2026
CAMBRIDGE, MASS., FEB. 04, 2026 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED THAT ...
Více zde

BIOGEN'S LITIFILIMAB RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR CUTANEOUS LUPUS ERYTHEMATOSUS, A DISEASE WITH NO TARGETED TREATMENT OPTIONS

28-01-2026
DESIGNATION IS BASED ON THE BREADTH OF AVAILABLE LITIFILIMAB DATA, INCLUDING THE PHASE 2 LILAC STUDY...
Více zde

FDA ACCEPTS LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER PRIORITY REVIEW

25-01-2026
IF APPROVED, LEQEMBI IQLIK WOULD BE THE FIRST AND ONLY ANTI-AMYLOID TREATMENT TO OFFER AT-HOME INJEC...
Více zde

BIOGEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR HIGH DOSE REGIMEN OF SPINRAZA® (NUSINERSEN) FOR SPINAL MUSCULAR ATROPHY

12-01-2026
CAMBRIDGE, MASS., JAN. 12, 2026 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED THE E...
Více zde

STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME

11-01-2026
BEDFORD, MASS.--(BUSINESS WIRE)--STOKE THERAPEUTICS, INC. (NASDAQ: STOK) IS A BIOTECHNOLOGY COMPANY ...
Více zde

BIOLOGICS LICENSE APPLICATION FOR SUBCUTANEOUS FORMULATION OF “LEQEMBI®” (LECANEMAB) FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE ACCEPTED IN CHINA

05-01-2026
IF APPROVED, LECANEMAB MAY BECOME THE FIRST AND ONLY ANTI-AMYLOID TREATMENT IN CHINA TO OFFER AN AT-...
Více zde

THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA) NEUROLOGY PUBLISHES LONG TERM RESULTS FROM THE QALSODY PHASE 3 VALOR STUDY AND ITS OPEN-LABEL EXTENSION IN SOD1-ALS

22-12-2025
CAMBRIDGE, MASS., DEC. 22, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) – TODAY ANNOUNCED T...
Více zde

BIOGEN RECEIVES HEALTH CANADA AUTHORIZATION FOR ZURZUVAE™ (ZURANOLONE), THE FIRST AND ONLY TREATMENT INDICATED FOR ADULTS WITH POSTPARTUM DEPRESSION IN CANADA

09-12-2025
TORONTO--(BUSINESS WIRE)--BIOGEN CANADA INC. TODAY ANNOUNCED THAT HEALTH CANADA HAS ISSUED A NOTICE ...
Více zde

“LEQEMBI®” (LECANEMAB) FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE INCLUDED IN CHINA'S COMMERCIAL INSURANCE INNOVATIVE DRUG LIST

08-12-2025
TOKYO AND CAMBRIDGE, MASS., DEC. 08, 2025 (GLOBE NEWSWIRE) -- EISAI CO., LTD. (HEADQUARTERS: TOKYO, ...
Více zde

BIOGEN AND STOKE THERAPEUTICS PRESENT DATA THAT FURTHER SUPPORT THE DISEASE-MODIFYING POTENTIAL OF ZOREVUNERSEN, AN INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME, AT THE 2025 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

05-12-2025
—LONG-TERM PHASE 1/2A AND OPEN LABEL EXTENSION (OLE) DATA FOR ZOREVUNERSEN ON TOP OF STANDARD OF C...
Více zde

EISAI PRESENTS NEW DATA ON THE CONTINUED AND EXPANDING BENEFIT OF LEQEMBI® (LECANEMAB-IRMB) MAINTENANCE TREATMENT IN EARLY ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE 2025

03-12-2025
LONG-TERM LEQEMBI TREATMENT SUGGESTS POTENTIAL TO DELAY DISEASE PROGRESSION FROM MILD COGNITIVE IMPA...
Více zde

NEW DATA PRESENTED AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE 2025 CONFIRMS PHARMACOLOGICAL EFFECT OF LEQEMBI® (LECANEMAB-IRMB) ON NEUROTOXIC AΒ PROTOFIBRILS IN CSF

02-12-2025
TOKYO AND CAMBRIDGE, MASS., DEC. 02, 2025 (GLOBE NEWSWIRE) -- EISAI CO., LTD. (HEADQUARTERS: TOKYO, ...
Více zde

STOKE THERAPEUTICS AND BIOGEN ANNOUNCE PRESENTATIONS AT THE 2025 AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

01-12-2025
BEDFORD, MASS. & CAMBRIDGE, MASS.--(BUSINESS WIRE)--STOKE THERAPEUTICS, INC. (NASDAQ: STOK), A BIOTE...
Více zde

EISAI SUBMITS NEW DRUG APPLICATION FOR SUBCUTANEOUS FORMULATION OF “LEQEMBI®” FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE IN JAPAN

27-11-2025
IF APPROVED, LECANEMAB WOULD BE THE FIRST AND ONLY ANTI-AMYLOID TREATMENT IN JAPAN TO OFFER AN AT-HO...
Více zde

EISAI COMPLETES ROLLING SUBMISSION TO US FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS

25-11-2025
LEQEMBI IQLIK, IF APPROVED FOR INITIATION DOSING, WOULD BE THE FIRST AND ONLY ANTI-AMYLOID TREATMENT...
Více zde

VERSANT VENTURES ANNOUNCES LAUNCH OF DAYRA THERAPEUTICS WITH FOUNDATIONAL BIOGEN PARTNERSHIP

24-11-2025
TORONTO & CAMBRIDGE, MASS.--(BUSINESS WIRE)--VERSANT VENTURES TODAY ANNOUNCED THE LAUNCH OF DAYRA TH...
Více zde

BIOGEN TO HIGHLIGHT NEW LECANEMAB DATA AND SCIENTIFIC ADVANCES AT THE 18TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE

20-11-2025
CAMBRIDGE, MASS., NOV. 20, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED UPCO...
Více zde

STOKE THERAPEUTICS AND BIOGEN ANNOUNCE PUBLICATION OF TWO-YEAR NATURAL HISTORY DATA DEMONSTRATING THE SEVERITY OF DRAVET SYNDROME, INCLUDING FREQUENT SEIZURES AND SIGNIFICANT COGNITIVE AND BEHAVIORAL IMPAIRMENTS

17-11-2025
BEDFORD, MASS., & CAMBRIDGE, MASS.--(BUSINESS WIRE)--STOKE THERAPEUTICS, INC. (NASDAQ: STOK), A BIOT...
Více zde

HIGH DOSE REGIMEN OF NUSINERSEN RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY

17-11-2025
CAMBRIDGE, MASS., NOV. 17, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED THE C...
Více zde

BIOGEN COMPLETES ACQUISITION OF ALCYONE THERAPEUTICS

14-11-2025
CAMBRIDGE, MASS., NOV. 14, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) HAS COMPLETED THE ACQ...
Více zde

“LEQEMBI®” (LECANEMAB) IV MAINTENANCE DOSING FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE APPROVED IN THE UNITED KINGDOM

13-11-2025
TOKYO AND CAMBRIDGE, MASS., NOV. 13, 2025 (GLOBE NEWSWIRE) -- EISAI CO., LTD. (HEADQUARTERS: TOKYO, ...
Více zde

BIOGEN TO HIGHLIGHT SCIENTIFIC PROGRESS IN RARE KIDNEY DISEASE AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025

03-11-2025
CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) – WILL PRESENT NEW ...
Více zde

SAMSUNG BIOEPIS TO COMMERCIALIZE BYOOVIZ® (RANIBIZUMAB) IN EUROPE FROM JANUARY 2026

29-10-2025
INCHEON, KOREA--(BUSINESS WIRE)-- #BYOOVIZ--SAMSUNG BIOEPIS CO., LTD. ANNOUNCED TODAY THAT THE COMPA...
Více zde

HEALTH CANADA GRANTS AUTHORIZATION FOR “LEQEMBI®” (LECANEMAB) FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE

26-10-2025
IN CANADA, LECANEMAB IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH A CLINICAL DIAGNOSIS OF M...
Více zde

BIOGEN LICENSES ORAL C5AR1 ANTAGONIST FROM VANQUA BIO TO EXPAND IMMUNOLOGY PORTFOLIO

24-10-2025
CAMBRIDGE, MASS. AND CHICAGO, OCT. 24, 2025 (GLOBE NEWSWIRE) --  BIOGEN INC. (NASDAQ: BIIB) AND VAN...
Více zde

BIOGEN TO PRESENT ADDITIONAL RESULTS FROM PHASE 3 STUDY OF DAPIROLIZUMAB PEGOL IN SYSTEMIC LUPUS ERYTHEMATOSUS AT ACR CONVERGENCE 2025

22-10-2025
CAMBRIDGE, MASS., OCT. 22, 2025 (GLOBE NEWSWIRE) -- BIOGEN INC. (NASDAQ: BIIB) TODAY ANNOUNCED UPCO...
Více zde

LEQEMBI® IQLIK™(LECANEMAB-IRMB) SUBCUTANEOUS AUTOINJECTOR NAMED TO TIME'S “BEST INVENTIONS OF 2025”

13-10-2025
TOKYO AND CAMBRIDGE, MASS., OCT. 13, 2025 (GLOBE NEWSWIRE) -- EISAI CO., LTD. (HEADQUARTERS: TOKYO, ...
Více zde

STOKE THERAPEUTICS AND BIOGEN PRESENT NEW DATA AT THE 54TH CHILD NEUROLOGY SOCIETY (CNS) ANNUAL MEETING THAT SUPPORT THE POTENTIAL OF ZOREVUNERSEN AS A DISEASE-MODIFYING MEDICINE FOR DRAVET SYNDROME

09-10-2025
BEDFORD, MASS., & CAMBRIDGE, MASS.--(BUSINESS WIRE)--STOKE THERAPEUTICS, INC. (NASDAQ: STOK), A BIOT...
Více zde

EISAI AND BIOGEN ANNOUNCE U.S. AVAILABILITY OF LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUBCUTANEOUS INJECTION MAINTENANCE DOSE FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE

06-10-2025
NEW LEQEMBI COMPANIONTM PROGRAM LAUNCHED TO EXPAND HELPFUL RESOURCES FOR PATIENTS THROUGHOUT THE TR...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-11 00:00:008-KStáhnout
2026-02-06 00:00:008-KStáhnout
2026-02-06 00:00:0010-KStáhnout
2026-01-14 00:00:008-KStáhnout
2025-10-30 00:00:008-KStáhnout
2025-10-30 00:00:0010-QStáhnout
2025-10-14 01:00:008-KStáhnout
2025-10-14 00:00:008-KStáhnout
2025-07-31 01:00:008-KStáhnout
2025-07-31 01:00:0010-QStáhnout
2025-07-31 00:00:008-KStáhnout
2025-07-31 00:00:0010-QStáhnout
2025-07-07 01:00:008-KStáhnout
2025-07-07 00:00:008-KStáhnout
2025-06-23 01:00:008-KStáhnout
2025-06-23 00:00:008-KStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 00:00:008-KStáhnout
2025-05-01 01:00:008-KStáhnout
2025-05-01 01:00:0010-QStáhnout
2025-05-01 00:00:008-KStáhnout
2025-05-01 00:00:0010-QStáhnout
2025-02-12 00:00:008-KStáhnout
2025-02-12 00:00:0010-KStáhnout
2025-02-11 23:00:008-KStáhnout
2025-02-11 23:00:0010-KStáhnout
2025-01-15 00:00:008-KStáhnout
2025-01-14 23:00:008-KStáhnout
2024-10-30 00:00:008-KStáhnout
2024-10-30 00:00:0010-QStáhnout
2024-10-29 23:00:008-KStáhnout
2024-10-29 23:00:0010-QStáhnout
2024-09-12 01:00:008-KStáhnout
2024-09-12 00:00:008-KStáhnout
2024-08-14 01:00:008-KStáhnout
2024-08-14 00:00:008-KStáhnout
2024-08-01 01:00:008-KStáhnout
2024-08-01 01:00:0010-QStáhnout
2024-08-01 00:00:008-KStáhnout
2024-08-01 00:00:0010-QStáhnout
2024-06-25 01:00:008-KStáhnout
2024-06-25 00:00:008-KStáhnout
2024-04-24 01:00:008-KStáhnout
2024-04-24 01:00:0010-QStáhnout
2024-04-24 00:00:008-KStáhnout
2024-04-24 00:00:0010-QStáhnout
2024-02-14 00:00:0010-KStáhnout
2024-02-13 23:00:0010-KStáhnout
2024-02-13 00:00:008-KStáhnout
2024-02-12 23:00:008-KStáhnout
2023-12-12 00:00:008-KStáhnout
2023-12-11 23:00:008-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-09-26 01:00:008-KStáhnout
2023-09-26 00:00:008-KStáhnout
2023-09-01 01:00:008-KStáhnout
2023-09-01 00:00:008-KStáhnout
2023-07-31 01:00:008-KStáhnout
2023-07-31 00:00:008-KStáhnout
2023-07-28 01:00:008-KStáhnout
2023-07-28 00:00:008-KStáhnout
2023-07-25 01:00:008-KStáhnout
2023-07-25 01:00:0010-QStáhnout
2023-07-25 00:00:008-KStáhnout
2023-07-25 00:00:0010-QStáhnout
2023-06-29 01:00:008-KStáhnout
2023-06-29 00:00:008-KStáhnout
2023-05-03 01:00:008-KStáhnout
2023-05-03 00:00:008-KStáhnout
2023-04-25 01:00:008-KStáhnout
2023-04-25 01:00:0010-QStáhnout
2023-04-25 00:00:008-KStáhnout
2023-04-25 00:00:0010-QStáhnout
2023-04-18 01:00:008-KStáhnout
2023-04-18 00:00:008-KStáhnout
2023-03-09 00:00:008-KStáhnout
2023-03-08 23:00:008-KStáhnout
2023-02-15 00:00:008-KStáhnout
2023-02-15 00:00:0010-KStáhnout
2023-02-14 23:00:008-KStáhnout
2023-02-14 23:00:0010-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-09 23:00:008-KStáhnout
2022-10-25 01:00:008-KStáhnout
2022-10-25 01:00:0010-QStáhnout
2022-10-25 00:00:008-KStáhnout
2022-10-25 00:00:0010-QStáhnout
2022-07-20 01:00:008-KStáhnout
2022-07-20 01:00:0010-QStáhnout
2022-07-20 00:00:008-KStáhnout
2022-07-20 00:00:0010-QStáhnout
2022-06-21 01:00:008-KStáhnout
2022-06-21 00:00:008-KStáhnout
2022-05-03 01:00:008-KStáhnout
2022-05-03 01:00:0010-QStáhnout
2022-05-03 00:00:008-KStáhnout
2022-05-03 00:00:0010-QStáhnout
2022-02-03 00:00:008-KStáhnout
2022-02-03 00:00:0010-KStáhnout
2022-02-02 23:00:008-KStáhnout
2022-02-02 23:00:0010-KStáhnout
2022-01-31 00:00:008-KStáhnout
2022-01-30 23:00:008-KStáhnout
2021-11-19 00:00:008-KStáhnout
2021-11-18 23:00:008-KStáhnout
2021-11-17 00:00:008-KStáhnout
2021-11-16 23:00:008-KStáhnout
2021-10-20 01:00:008-KStáhnout
2021-10-20 01:00:0010-QStáhnout
2021-10-20 00:00:008-KStáhnout
2021-10-20 00:00:0010-QStáhnout
2021-07-22 01:00:008-KStáhnout
2021-07-22 01:00:0010-QStáhnout
2021-07-22 00:00:008-KStáhnout
2021-07-22 00:00:0010-QStáhnout
2021-06-08 01:00:008-KStáhnout
2021-06-08 00:00:008-KStáhnout
2021-04-22 01:00:008-KStáhnout
2021-04-22 01:00:0010-QStáhnout
2021-04-22 00:00:008-KStáhnout
2021-04-22 00:00:0010-QStáhnout
2021-04-09 01:00:008-KStáhnout
2021-04-09 00:00:008-KStáhnout
2021-02-16 00:00:008-KStáhnout
2021-02-15 23:00:008-KStáhnout
2021-02-04 00:00:008-KStáhnout
2021-02-03 23:00:008-KStáhnout
2021-02-03 00:00:008-KStáhnout
2021-02-03 00:00:0010-KStáhnout
2021-02-02 23:00:008-KStáhnout
2021-02-02 23:00:0010-KStáhnout
2020-10-21 01:00:008-KStáhnout
2020-10-21 01:00:0010-QStáhnout
2020-10-21 00:00:008-KStáhnout
2020-10-21 00:00:0010-QStáhnout
2020-09-21 01:00:008-KStáhnout
2020-09-21 00:00:008-KStáhnout
2020-07-22 01:00:008-KStáhnout
2020-07-22 01:00:0010-QStáhnout
2020-07-22 00:00:008-KStáhnout
2020-07-22 00:00:0010-QStáhnout
2020-06-18 01:00:008-KStáhnout
2020-06-18 00:00:008-KStáhnout
2020-06-05 01:00:008-KStáhnout
2020-06-05 00:00:008-KStáhnout
2020-04-30 01:00:008-KStáhnout
2020-04-30 00:00:008-KStáhnout
2020-04-23 01:00:0010-QStáhnout
2020-04-23 00:00:0010-QStáhnout
2020-04-22 01:00:008-KStáhnout
2020-04-22 00:00:008-KStáhnout
2020-04-20 01:00:008-KStáhnout
2020-04-20 00:00:008-KStáhnout
2020-02-06 00:00:0010-KStáhnout
2020-02-05 23:00:0010-KStáhnout
2020-02-03 00:00:008-KStáhnout
2020-02-02 23:00:008-KStáhnout
2020-01-30 00:00:008-KStáhnout
2020-01-29 23:00:008-KStáhnout
2019-12-19 00:00:008-KStáhnout
2019-12-18 23:00:008-KStáhnout
2019-10-22 01:00:008-KStáhnout
2019-10-22 01:00:0010-QStáhnout
2019-10-22 00:00:008-KStáhnout
2019-10-22 00:00:0010-QStáhnout
2019-10-01 01:00:008-KStáhnout
2019-10-01 00:00:008-KStáhnout
2019-07-24 01:00:0010-QStáhnout
2019-07-24 00:00:0010-QStáhnout
2019-07-23 01:00:008-KStáhnout
2019-07-23 00:00:008-KStáhnout
2019-06-20 01:00:008-KStáhnout
2019-06-20 00:00:008-KStáhnout
2019-05-15 01:00:008-KStáhnout
2019-05-15 00:00:008-KStáhnout
2019-04-29 01:00:008-KStáhnout
2019-04-29 00:00:008-KStáhnout
2019-04-24 01:00:008-KStáhnout
2019-04-24 01:00:0010-QStáhnout
2019-04-24 00:00:008-KStáhnout
2019-04-24 00:00:0010-QStáhnout
2019-03-25 00:00:008-KStáhnout
2019-03-24 23:00:008-KStáhnout
2019-02-06 00:00:0010-KStáhnout
2019-02-05 23:00:0010-KStáhnout
2019-01-29 00:00:008-KStáhnout
2019-01-28 23:00:008-KStáhnout
2018-11-01 00:00:008-KStáhnout
2018-10-31 23:00:008-KStáhnout
2018-10-23 01:00:008-KStáhnout
2018-10-23 01:00:0010-QStáhnout
2018-10-23 00:00:008-KStáhnout
2018-10-23 00:00:0010-QStáhnout
2018-08-03 01:00:008-KStáhnout
2018-08-03 00:00:008-KStáhnout
2018-07-24 01:00:008-KStáhnout
2018-07-24 01:00:0010-QStáhnout
2018-07-24 00:00:008-KStáhnout
2018-07-24 00:00:0010-QStáhnout
2018-06-26 01:00:008-KStáhnout
2018-06-26 00:00:008-KStáhnout
2018-06-15 01:00:008-KStáhnout
2018-06-15 00:00:008-KStáhnout
2018-04-24 01:00:008-KStáhnout
2018-04-24 01:00:0010-QStáhnout
2018-04-24 00:00:008-KStáhnout
2018-04-24 00:00:0010-QStáhnout
2018-02-01 00:00:0010-KStáhnout
2018-01-31 23:00:0010-KStáhnout
2018-01-25 00:00:008-KStáhnout
2018-01-24 23:00:008-KStáhnout
2017-11-21 00:00:008-KStáhnout
2017-11-20 23:00:008-KStáhnout
2017-11-07 00:00:008-KStáhnout
2017-11-06 23:00:008-KStáhnout
2017-10-24 01:00:008-KStáhnout
2017-10-24 01:00:0010-QStáhnout
2017-10-24 00:00:008-KStáhnout
2017-10-24 00:00:0010-QStáhnout
2017-07-25 01:00:008-KStáhnout
2017-07-25 01:00:0010-QStáhnout
2017-07-25 00:00:008-KStáhnout
2017-07-25 00:00:0010-QStáhnout
2017-06-13 01:00:008-KStáhnout
2017-06-13 00:00:008-KStáhnout
2017-06-09 01:00:008-KStáhnout
2017-06-09 00:00:008-KStáhnout
2017-04-25 01:00:008-KStáhnout
2017-04-25 01:00:0010-QStáhnout
2017-04-25 00:00:008-KStáhnout
2017-04-25 00:00:0010-QStáhnout
2017-02-02 00:00:008-KStáhnout
2017-02-02 00:00:0010-KStáhnout
2017-02-01 23:00:008-KStáhnout
2017-02-01 23:00:0010-KStáhnout
2017-02-01 00:00:008-KStáhnout
2017-01-31 23:00:008-KStáhnout
2017-01-26 00:00:008-KStáhnout
2017-01-25 23:00:008-KStáhnout
2017-01-17 00:00:008-KStáhnout
2017-01-16 23:00:008-KStáhnout
2016-12-19 00:00:008-KStáhnout
2016-12-18 23:00:008-KStáhnout
2016-12-12 00:00:008-KStáhnout
2016-12-11 23:00:008-KStáhnout
2016-10-26 01:00:008-KStáhnout
2016-10-26 01:00:0010-QStáhnout
2016-10-26 00:00:008-KStáhnout
2016-10-26 00:00:0010-QStáhnout
2016-07-21 01:00:008-KStáhnout
2016-07-21 01:00:0010-QStáhnout
2016-07-21 00:00:008-KStáhnout
2016-07-21 00:00:0010-QStáhnout
2016-06-21 01:00:008-KStáhnout
2016-06-21 00:00:008-KStáhnout
2016-06-09 01:00:008-KStáhnout
2016-06-09 00:00:008-KStáhnout
2016-05-03 01:00:008-KStáhnout
2016-05-03 00:00:008-KStáhnout
2016-04-29 01:00:008-KStáhnout
2016-04-29 00:00:008-KStáhnout
2016-04-21 01:00:008-KStáhnout
2016-04-21 01:00:0010-QStáhnout
2016-04-21 00:00:008-KStáhnout
2016-04-21 00:00:0010-QStáhnout
2016-02-03 00:00:0010-KStáhnout
2016-02-02 23:00:0010-KStáhnout
2016-01-27 00:00:008-KStáhnout
2016-01-26 23:00:008-KStáhnout
2015-10-21 01:00:008-KStáhnout
2015-10-21 01:00:0010-QStáhnout
2015-10-21 00:00:008-KStáhnout
2015-10-21 00:00:0010-QStáhnout
2015-09-16 01:00:008-KStáhnout
2015-09-16 00:00:008-KStáhnout
2015-09-14 01:00:008-KStáhnout
2015-09-14 00:00:008-KStáhnout
2015-09-01 01:00:008-KStáhnout
2015-09-01 00:00:008-KStáhnout
2015-07-24 01:00:008-KStáhnout
2015-07-24 01:00:0010-QStáhnout
2015-07-24 00:00:008-KStáhnout
2015-07-24 00:00:0010-QStáhnout
2015-06-11 01:00:008-KStáhnout
2015-06-11 00:00:008-KStáhnout
2015-04-24 01:00:008-KStáhnout
2015-04-24 01:00:0010-QStáhnout
2015-04-24 00:00:008-KStáhnout
2015-04-24 00:00:0010-QStáhnout
2015-03-27 00:00:008-KStáhnout
2015-03-26 23:00:008-KStáhnout
2015-02-04 00:00:0010-KStáhnout
2015-02-03 23:00:0010-KStáhnout
2015-01-29 00:00:008-KStáhnout
2015-01-28 23:00:008-KStáhnout
2014-10-22 01:00:008-KStáhnout
2014-10-22 01:00:0010-QStáhnout
2014-10-22 00:00:008-KStáhnout
2014-10-22 00:00:0010-QStáhnout
2014-07-23 01:00:008-KStáhnout
2014-07-23 01:00:0010-QStáhnout
2014-07-23 00:00:008-KStáhnout
2014-07-23 00:00:0010-QStáhnout
2014-06-13 01:00:008-KStáhnout
2014-06-13 00:00:008-KStáhnout
2014-04-23 01:00:008-KStáhnout
2014-04-23 01:00:0010-QStáhnout
2014-04-23 00:00:008-KStáhnout
2014-04-23 00:00:0010-QStáhnout
2014-02-18 00:00:008-KStáhnout
2014-02-17 23:00:008-KStáhnout
2014-02-06 00:00:0010-KStáhnout
2014-02-05 23:00:0010-KStáhnout
2014-01-29 00:00:008-KStáhnout
2014-01-28 23:00:008-KStáhnout
2013-10-28 00:00:008-KStáhnout
2013-10-28 00:00:0010-QStáhnout
2013-10-27 23:00:008-KStáhnout
2013-10-27 23:00:0010-QStáhnout
2013-08-26 01:00:008-KStáhnout
2013-08-26 00:00:008-KStáhnout
2013-07-25 01:00:008-KStáhnout
2013-07-25 01:00:0010-QStáhnout
2013-07-25 00:00:008-KStáhnout
2013-07-25 00:00:0010-QStáhnout
2013-06-14 01:00:008-KStáhnout
2013-06-14 00:00:008-KStáhnout
2013-05-30 01:00:008-KStáhnout
2013-05-30 00:00:008-KStáhnout
2013-04-25 01:00:008-KStáhnout
2013-04-25 01:00:0010-QStáhnout
2013-04-25 00:00:008-KStáhnout
2013-04-02 01:00:008-KStáhnout
2013-04-02 00:00:008-KStáhnout
2013-03-14 00:00:008-KStáhnout
2013-03-13 23:00:008-KStáhnout
2013-02-05 23:00:008-KStáhnout
preloader